PHVS
Price
$34.18Alerts
Change
+$0.19 (+0.56%)
Updated
Nov 11 closing price
Capitalization
2.41B
Earnings call today
Intraday BUY SELL Signals
SYRE
Price
$106.82Alerts
Change
+$2.34 (+2.24%)
Updated
Nov 11 closing price
Capitalization
9.16B
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PHVS vs SYRE

PHVS vs SYRE Comparison Chart in %
View a ticker or compare two or three
VS
PHVS vs. SYRE commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHVS is a Hold and SYRE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PHVS with price predictions
Nov 10, 2026

PHVS in upward trend: price rose above 50-day moving average on November 06, 2026

PHVS moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on PHVS as a result. In 98 of 111 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

The Moving Average Convergence Divergence (MACD) for PHVS just turned positive on October 20, 2026. Looking at past instances where PHVS's MACD turned positive, the stock continued to rise in 49 of 55 cases over the following month. The odds of a continued upward trend are 89%.

The 10-day moving average for PHVS crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHVS advanced for three days, in 192 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

PHVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for PHVS moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 59 cases where PHVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for PHVS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.026) is normal, around the industry mean (3.498). P/E Ratio (-13.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PHVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for SYRE with price predictions
Nov 10, 2026

SYRE's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Indicator for SYRE moved out of overbought territory on November 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 24 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

SYRE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 65 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.

SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +12.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 261 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

The Aroon Indicator entered an Uptrend today. In 148 of 174 cases where SYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.592) is normal, around the industry mean (3.498). P/E Ratio (-54.111) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
84
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
54
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PHVSSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
87%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (PHVS: $33.99 vs. SYRE: $106.82)
Brand notoriety: PHVS and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHVS: 91% vs. SYRE: 73%
Market capitalization -- PHVS: $2.41B vs. SYRE: $9.16B
PHVS [@Biotechnology] is valued at $2.41B. SYRE’s [@Biotechnology] market capitalization is $9.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHVS’s FA Score shows that 1 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).

  • PHVS’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, PHVS is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHVS’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • PHVS’s TA Score: 6 bullish, 4 bearish.
  • SYRE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both PHVS and SYRE are a good buy in the short-term.

Price Growth

PHVS (@Biotechnology) experienced а -2.27% price change this week, while SYRE (@Biotechnology) price change was +7.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

PHVS is expected to report earnings on Nov 11, 2026.

SYRE is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

PHVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHVS has been loosely correlated with IMNM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PHVS jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHVS
1D Price
Change %
PHVS100%
-1.39%
IMNM - PHVS
46%
Loosely correlated
-3.67%
SYRE - PHVS
46%
Loosely correlated
-4.15%
SVRA - PHVS
42%
Loosely correlated
-2.57%
MGTX - PHVS
41%
Loosely correlated
+1.37%
AXSM - PHVS
40%
Loosely correlated
+5.23%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RMT13.400.21
+1.59%
Royce Micro-Cap Trust
XFEB38.470.16
+0.41%
FT Vest U.S. Equity Enhance & Moderate Buffer ETF - February (XFEB)
XLU43.820.09
+0.21%
State Street Utilities Select Sector SPDR ETF (XLU)
KPDD4.86N/A
N/A
KraneShares 2x Long PDD Daily ETF (KPDD)
RWM14.17-0.13
-0.91%
ProShares Short Russell2000 (RWM)